Ikarian Capital’s Larimar Therapeutics LRMR Stock Holding History

Ikarian Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-548,400	Closed	-$1.77M	–	203
2025 Q3	$1.77M	Buy	+548,400	New	+$2.06M	0.18%	104

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ikarian Capital's LRMR Position: Q2 2025 in Review

Ikarian Capital sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 58,526 shares — an estimated $126K sold.

Ikarian Capital first reported a position in LRMR in Q1 2021 and held it in 13 quarters. The position peaked at $6.21M in Q1 2021. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

Ikarian Capital reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 58,526 Larimar Therapeutics shares in Q2 2025, an estimated $126K.
Ikarian Capital first reported a position in Larimar Therapeutics in Q1 2021 and held it in 13 quarters.
Ikarian Capital's Larimar Therapeutics position peaked at $6.21M in Q1 2021.
116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.